Multiparametric cardiac 18F-FDG PET in humans: pilot comparison of FDG delivery rate with 82Rb myocardial blood flow

Myocardial blood flow (MBF) and flow reserve are usually quantified in the clinic with positron emission tomography (PET) using a perfusion-specific radiotracer (e.g. ⁸²Rb-chloride). However, the clinical accessibility of existing perfusion tracers remains limited. Meanwhile, ¹⁸F-fluorodeoxyglucose (FDG) is a commonly used radiotracer for PET metabolic imaging without similar limitations. In this paper, we explore the potential of ¹⁸F-FDG for myocardial perfusion imaging by comparing the myocardial FDG delivery rate K₁ with MBF as determined by dynamic ⁸²Rb PET in fourteen human subjects with heart disease. Two sets of FDG K₁ were derived from one-hour dynamic FDG scans. One was the original FDG K₁ estimates and the other was the corresponding K₁ values that were linearly normalized for blood glucose levels. A generalized Renkin-Crone model was used to fit FDG K₁ with Rb MBF, which then allowed for a nonlinear extraction fraction correction for converting FDG K₁ to MBF. The linear correlation between FDG-derived MBF and Rb MBF was moderate (r = 0.79) before the glucose normalization and became much improved (r > 0.9) after glucose normalization. The extraction fraction of FDG was also similar to that of Rb-chloride in the myocardium. The results from this pilot study suggest that dynamic cardiac FDG-PET with tracer kinetic modeling has the potential to provide MBF in addition to its conventional use for metabolic imaging.